Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 30
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Boston Scientific Corp
BSX
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$41.98
-0.71
-1.66%
Dern. MÀJ: Oct 30, 6:59 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Résultats:
Les résultats Q3 2026 ont été publiés le mer. oct. 28th, avant l'ouverture du marché
Conférence téléphonique:
La conférence téléphonique la plus récente a commencé à 8:00 AM, il y a 2 jours
Cliquez pour voir la webdiffusion
Boston Scientific Financials
Boston Scientific (BSX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results
Boston Scientific beat Q3 estimates but cut FY26 guidance; Q4 forecasts missed expectations. Analysts adjusted price targets.
Avi Kapoor
Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance
Boston Scientific slips after a cyber fallout offsets a Q3 consensus beat. Management targets a 2027 cycle trough and 2030 expansion.
Vandana Singh
PRO
Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 Est; Lowers FY2026 Sales Guidance from $21.178B-$21.379B to $20.927B vs $21.143B Est
Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 analyst estimate. Lowers FY2026 sales outlook from $21.178 billion-$21.379 billion to $20.927 billion vs $21.143
Benzinga Newsdesk
PRO
Boston Scientific Sees Q4 Adj EPS $0.77-$0.79 vs $0.84 Est; Sees Sales $5.127B-$5.233B vs $5.404B Est
Boston Scientific (NYSE:BSX) is looking for Q4 Adj EPS of $0.77-$0.79 vs $0.84 analyst estimate. sees sales of $5.127 billion-$5.233 billion vs $5.404 billion analyst estimate.
Benzinga Newsdesk
PRO
Boston Scientific Q3 Adj. EPS $0.73 Beats $0.72 Estimate, Sales $5.138B Beat $5.046B Estimate
Boston Scientific (NYSE:BSX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.72 by 1.39 percent. This is a 2.67 percent decrease over earnings of $0.75 per share from the
Benzinga Newsdesk
Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test
Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco Santander, UBS Group
Benzinga Insights
